Literature DB >> 8285645

In vitro activities of antimicrobial agents against clinical isolates of Flavimonas oryzihabitans obtained from patients with cancer.

K V Rolston1, D H Ho, B LeBlanc, G P Bodey.   

Abstract

We evaluated the in vitro activities of 21 different antimicrobial agents against nine clinical isolates of Flavimonas oryzihabitans obtained from patients with cancer. The organisms were susceptible to most agents commonly used for the empiric therapy (aminoglycosides, ureidopenicillins, extended-spectrum cephalosporins, monobactams, and carbapenems) and prevention of infections (quinolones and trimethoprim-sulfamethoxazole) in this patient population.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8285645      PMCID： PMC192420          DOI： 10.1128/AAC.37.11.2504

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Characteristics of yellow-pigmented nonfermentative bacilli (groups VE-1 and VE-2) encountered in clinical bacteriology.

Authors:  G L Gilardi; S Hirschl; M Mandel
Journal:  J Clin Microbiol       Date:  1975-04       Impact factor: 5.948

2.  In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

Authors:  K V Rolston; H T Nguyen; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

3.  Flavimonas oryzihabitans (formerly CDC group Ve-2) bacteremia in a pediatric patient on assisted ventilation.

Authors:  J Reina; J Odgardd; I Llompart; P Alomar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

4.  Flavimonas oryzihabitans (Pseudomonas oryzihabitans; CDC group Ve-2): an emerging pathogen in peritonitis related to continuous ambulatory peritoneal dialysis?

Authors:  J W Bendig; P J Mayes; D E Eyers; B Holmes; T T Chin
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

5.  Isolation of Flavimonas oryzihabitans (CDC group Ve-2) from catheter-induced bacteremia in an immunocompromised patient.

Authors:  R Mutters; H Köppler; T Krause
Journal:  Eur J Epidemiol       Date:  1990-12       Impact factor: 8.082

6.  Flavimonas oryzihabitans infection of a surgical wound.

Authors:  R Munro; G Buckland; S Neville
Journal:  Pathology       Date:  1990-10       Impact factor: 5.306

Review 7.  Infections with Chryseomonas luteola (CDC group Ve-1) and Flavimonas oryzihabitans (CDC group Ve-2) in neurosurgical patients.

Authors:  J R Kostman; F Solomon; T Fekete
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

Review 8.  Serious infections involving the CDC group Ve bacteria Chryseomonas luteola and Flavimonas oryzihabitans.

Authors:  R E Hawkins; R A Moriarty; D E Lewis; E C Oldfield
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

Review 9.  Flavimonas oryzihabitans septicaemia in a T-cell leukaemic child: a case report and review of the literature.

Authors:  A Podbielski; R Mertens; C Ziebold; A Kaufhold
Journal:  J Infect       Date:  1990-03       Impact factor: 6.072

Review 10.  In vitro susceptibilities of nonfermentative gram-negative bacilli other than Pseudomonas aeruginosa to 32 antimicrobial agents.

Authors:  R J Fass; J Barnishan
Journal:  Rev Infect Dis       Date:  1980 Nov-Dec
View more
  4 in total

1.  A rare cause of peritonitis caused by Flavimonas oryzihabitans in continuous ambulatory peritoneal dialysis (CAPD).

Authors:  Stamatina Papakonstantinou; Evangelia Dounousi; Kyriakos Ioannou; Ioannis Tsouchnikas; Apostolos Kelesidis; Nikolaos Kotzadamis; Dimitrios Tsakiris
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

2.  Haemorrhagic papular rash associated to Flavimonas oryzihabitans bacteraemia in a child.

Authors:  A Kansouzidou; C Charitidou; E Poubrou; V D Daniilidis; H Tsagaropoulou
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

3.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

Authors:  M A Visalli; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Authors:  S K Spangler; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.